MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

doi:10.1053/j.gastro.2019.11.312

Review

. 2020 May;158(7):1999-2014.e1.

doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Mohammed Eslam¹, Arun J Sanyal², Jacob George³; International Consensus Panel

Collaborators, Affiliations

Affiliations

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia. Electronic address: mohammed.eslam@sydney.edu.au.
² Virginia Commonwealth University School of Medicine, Richmond, Virginia. Electronic address: arun.sanyal@vcuhealth.org.
³ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia. Electronic address: jacob.george@sydney.edu.au.

PMID: 32044314
DOI: 10.1053/j.gastro.2019.11.312

Review

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Mohammed Eslam et al. Gastroenterology. 2020 May.

. 2020 May;158(7):1999-2014.e1.

doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.

Authors

Mohammed Eslam¹, Arun J Sanyal², Jacob George³; International Consensus Panel

Affiliations

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia. Electronic address: mohammed.eslam@sydney.edu.au.
² Virginia Commonwealth University School of Medicine, Richmond, Virginia. Electronic address: arun.sanyal@vcuhealth.org.
³ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia. Electronic address: jacob.george@sydney.edu.au.

PMID: 32044314
DOI: 10.1053/j.gastro.2019.11.312

Abstract

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease "MAFLD" was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.

Keywords: Heterogeneity; MAFLD; Metabolic; Nomenclature.

PubMed Disclaimer

Comment in

Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease.
Valencia-Rodríguez A, Vera-Barajas A, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. Valencia-Rodríguez A, et al. Ann Hepatol. 2020 May-Jun;19(3):227-229. doi: 10.1016/j.aohep.2020.04.001. Ann Hepatol. 2020. PMID: 32359519 English. No abstract available.
From NAFLD to MAFLD: when pathophysiology succeeds.
Tilg H, Effenberger M. Tilg H, et al. Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. doi: 10.1038/s41575-020-0316-6. Epub 2020 May 27. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32461575 No abstract available.
Non-alcoholic fatty liver disease: Not time for an obituary just yet!
Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. Singh SP, et al. J Hepatol. 2021 Apr;74(4):972-974. doi: 10.1016/j.jhep.2020.10.015. Epub 2020 Dec 16. J Hepatol. 2021. PMID: 33340575 No abstract available.
Yet more evidence that MAFLD is more than a name change.
Eslam M, Ratziu V, George J. Eslam M, et al. J Hepatol. 2021 Apr;74(4):977-979. doi: 10.1016/j.jhep.2020.12.025. Epub 2021 Jan 13. J Hepatol. 2021. PMID: 33453331 No abstract available.
The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
Spearman CW, Desalegn H, Ocama P, Awuku YA, Ojo O, Elsahhar M, Abdo AA, Ndububa DA, Fouad Y, Borodo MM, Ng'wanasayi M, Ally R, Elwakil R. Spearman CW, et al. J Hepatol. 2021 May;74(5):1256-1258. doi: 10.1016/j.jhep.2021.01.015. Epub 2021 Jan 20. J Hepatol. 2021. PMID: 33484771 No abstract available.
Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
Alem SA, Gaber Y, Abdalla M, Said E, Fouad Y. Alem SA, et al. J Hepatol. 2021 May;74(5):1261-1262. doi: 10.1016/j.jhep.2021.01.022. Epub 2021 Jan 23. J Hepatol. 2021. PMID: 33497764 No abstract available.
Non-alcoholic steatohepatitis or metabolic-associated fatty liver: time to change.
Shiha G, Mousa N. Shiha G, et al. Hepatobiliary Surg Nutr. 2021 Jan;10(1):123-125. doi: 10.21037/hbsn-20-438. Hepatobiliary Surg Nutr. 2021. PMID: 33575301 Free PMC article. No abstract available.
Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Fouad Y, et al. J Hepatol. 2021 May;74(5):1254-1256. doi: 10.1016/j.jhep.2020.12.035. Epub 2021 Feb 11. J Hepatol. 2021. PMID: 33582129 No abstract available.
MAFLD: Now is the time to capitalize on the momentum.
Eslam M, George J. Eslam M, et al. J Hepatol. 2021 May;74(5):1262-1263. doi: 10.1016/j.jhep.2021.02.002. Epub 2021 Feb 12. J Hepatol. 2021. PMID: 33587953 No abstract available.

Cited by

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Boettler T, et al. JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169. Epub 2020 Aug 4. JHEP Rep. 2020. PMID: 32835190 Free PMC article. Review.
Treatments for NAFLD: State of Art.
Mantovani A, Dalbeni A. Mantovani A, et al. Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350. Int J Mol Sci. 2021. PMID: 33652942 Free PMC article. Review.
Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.
Albhaisi S, Sanyal AJ. Albhaisi S, et al. Front Endocrinol (Lausanne). 2021 May 10;12:665987. doi: 10.3389/fendo.2021.665987. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34040583 Free PMC article. Review.
Machine learning prediction of hepatic steatosis using body composition parameters: A UK Biobank Study.
Boncan DAT, Yu Y, Zhang M, Lian J, Vardhanabhuti V. Boncan DAT, et al. NPJ Aging. 2024 Jan 9;10(1):4. doi: 10.1038/s41514-023-00127-z. NPJ Aging. 2024. PMID: 38195699 Free PMC article.
Development and Validation of a Nomogram for Prediction of the Risk of MAFLD in an Overweight and Obese Population.
Song D, Ge Q, Chen M, Bai S, Lai X, Huang G, Liu M, Lin M, Xu J, Dong F. Song D, et al. J Clin Transl Hepatol. 2022 Dec 28;10(6):1027-1033. doi: 10.14218/JCTH.2021.00317. Epub 2022 Feb 28. J Clin Transl Hepatol. 2022. PMID: 36381091 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

DH_/Department of Health/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Collaborators

Affiliations

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Authors

Collaborators

Affiliations

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical